arznei-telegramm® 02/2016 |
REVIEW |
On the benefit of standard vaccines: tetanus |
NEW ON THE MARKET |
Idarucizumab (PRAXBIND): antidote for dabigatran |
a-t READER'S QUESTIONS AND COMMENTS |
Red yeast rice: withdrawal of products from the market is overdue |
Is it allowed to substitute immediate-release preparations for prolonged-release preparations? |
IN BRIEF |
Rivaroxaban (XARELTO) rehabilitated? |
Betahistine (e.g. VASOMOTAL) for MENIÈRE´s disease |
Fusafungine (LOCABIOSOL): withdrawal from the market recommended |
Misleading trade names of painkillers |
Error analysis: BIA 10-2474 in phase 1 testing |
CURRENT ADR NETWORK REPORT | Urinary incontinence due to safinamide (XADAGO)? |
SIDE EFFECTS |
e a-t IN THE INTERNET |
Dimethyl fumarate (TECFIDERA): first progressive multifocal leukoencephalopathy with only moderate lymphopenia |